|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 668270-12-0 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
Fields of Application :
Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
| CAS Number: | 668270-12-0 |
| Purity: | >98% |
| Molecular Weight: | 472.54 |
| Molecular Formula: | C25H28N8O2 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | BI1356, BI 1356 |
| Chemical Name: | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Description of Linagliptin: Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim For treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 For treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. For the detailed information about the solubility of Linagliptin (BI-1356) in water, the solubility of Linagliptin (BI-1356) in DMSO, the solubility of Linagliptin (BI-1356) in PBS buffer, the animal experiment（test） of Linagliptin (BI-1356),the in vivo,in vitro and clinical trial test of Linagliptin (BI-1356),the cell experiment（test） of Linagliptin (BI-1356),the IC50, EC50 and Affinity of Linagliptin (BI-1356).
References:
CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
